1 Regional 4D Cardiac Magnetic Resonance Strain Predicts Cardiomyopathy

2 **Progression in Duchenne Muscular Dystrophy**

- 3
- 4 Conner C. Earl^{1,2}, BS; Alexa M. Jauregui^{1,2}, BS; Guang Lin³, PhD; Kan N. Hor⁴, MD;
- 5 Larry W. Markham⁵, MD; Jonathan H. Soslow⁶, MD; Craig J. Goergen^{1,2}, PhD
- 6 7

8

- 1. Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN
- 2. Indiana University School of Medicine, Indianapolis, IN
- 9 3. Department of Mathematics & School of Mechanical Engineering, Purdue
 10 University, West Lafayette, IN
- The Heart Center, Nationwide Children's Hospital, Ohio State University,
 Columbus, OH, USA
- Division of Pediatric Cardiology, Riley Children's Hospital at Indiana University
 Health, Indiana University School of Medicine, Indianapolis, IN
- Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University
 Medical Center
- 17 Short Title: Regional 4D CMR Strain Predicts Progression in DMD CMP
- 18

Corresponding Authors:

Craig J. Goergen, PhD, FAHAJonathan H. Soslow, MD, MSCI206 S. Martin Jischke Drive2200 Children's Way 5th Floor,West Lafayette, IN 47907, USANashville, TN 37232, USAcgoergen@purdue.edujonathan.h.soslow@vumc.org

| 19 | | | |
|----|--|--|--|
| 20 | | | |
| 21 | | | |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| 25 | | | |
| 26 | | | |
| 27 | | | |
| 28 | | | |
| 29 | | | |
| | | | |

30 Abstract:

31 **Background:** Cardiomyopathy (CMP) is the leading cause of death in Duchenne

- 32 muscular dystrophy (DMD). Characterization of disease trajectory can be challenging,
- 33 especially in the early stage of CMP where onset and clinical progression may vary.
- 34 Traditional metrics from cardiovascular magnetic resonance (CMR) imaging such as
- 35 LVEF (left ventricular ejection fraction) and LGE (late gadolinium enhancement) are
- 36 often insufficient for assessing disease trajectory. We hypothesized that strain patterns
- 37 from a novel 4D (3D+time) CMR regional strain analysis method can be used to predict
- 38 the rate of DMD CMP progression.
- 39

40 Methods: We compiled 115 short-axis cine CMR image stacks for n=40 pediatric DMD 41 patients (13.6±4.2 years) imaged yearly for 3 consecutive visits and computed regional 42 strain metrics using custom-built feature tracking software. We measured regional strain 43 parameters by determining the relative change in the localized 4D endocardial surface 44 mesh using end diastole as the initial reference frame.

45

Results: We first separated patients into two cohorts based on their initial CMR: 46 47 LVEF≥55% (n=28, normal cohort) and LVEF<55% (n=12, abnormal cohort). Using 48 LVEF decrease measured two years following the initial scan, we further subclassified 49 these cohorts into slow (Δ LVEF% \leq 5) or fast (Δ LVEF%>5) progression groups for both 50 the normal cohort (n=12, slow; n=15, fast) and the abnormal cohort (n=8, slow; n=4, 51 fast). There was no statistical difference between the slow and fast progression groups in standard biomarkers such as LVEF, age, or LGE status. However, basal 52 53 circumferential strain (E_{cc}) late diastolic strain rate and basal surface area strain (E_{a}) 54 late diastolic strain rate magnitude were significantly decreased in fast progressors in both normal and abnormal cohorts (p<0.01, p=0.04 and p<0.01, p=0.02, respectively). 55 Peak E_a and E_{cc} magnitudes were also decreased in fast progressors, though these 56 57 only reached statistical significance in the normal cohort (p < 0.01, p = 0.24 and p < 0.01, 58 p=0.18, respectively).

- 60 **Conclusion:** Regional strain metrics from 4D CMR can be used to differentiate
- 61 between slow or fast CMP progression in a longitudinal DMD cohort. These results
- 62 demonstrate that 4D CMR strain is useful for early identification of CMP progression in
- 63 patients with DMD.
- 64

65 **Clinical Perspective:**

- Cardiomyopathy is the number one cause of death in Duchenne muscular dystrophy, 66 but the onset and progression of the disease are variable and heterogeneous. In this 67 study, we used a novel 4D cardiovascular magnetic resonance regional strain analysis 68 69 method to evaluate 40 pediatric Duchenne patients over three consecutive annual visits. 70 From our analysis, we found that peak systolic strain and late diastolic strain rate were early indicators of cardiomyopathy progression. This method offers promise for early 71 72 detection and monitoring, potentially improving patient outcomes through timely 73 intervention and management.
- 74

75 Key Words: Duchenne muscular dystrophy, cardiomyopathy, strain, gadolinium,

76 progression, Left ventricular function, Diastolic dysfunction.

77

78 Introduction:

- 79 Duchenne muscular dystrophy (DMD) is a devastating X-linked genetic disease
- 80 characterized by progressive muscle weakness, loss of mobility, and often a
- 81 dramatically shortened lifespan¹⁻³. Muscle weakness and loss of ambulation are
- 82 hallmark features of this disease, however, DMD-associated cardiomyopathy (CMP) is
- the number one cause of death in this population^{4, 5}. While there is no cure for DMD,
- 84 advancements in research and medical care have enhanced the quality of life and
- 85 extended the life expectancy of individuals affected by this condition^{4, 6}.
- 86 Among the various developments in the management of DMD, cardiac magnetic
- 87 resonance imaging (CMR) has emerged as the gold standard tool for assessing cardiac
- involvement and tracking the progression of this disease⁷⁻¹⁰. However, given the
- inherent variability in the onset and clinical progression of DMD, characterizing the

trajectory of the disease, particularly in the early stages of CMP, presents a notable
 challenge¹¹.

92

CMR-derived metrics most often used in disease assessment include left ventricular 93 94 ejection fraction (LVEF) and late gadolinium enhancement (LGE)⁷. LVEF is a wellaccepted indicator of overall systolic function, but a decrease in LVEF below clinically 95 96 normal levels often occurs only after substantial disease progression¹¹. LGE is an 97 indicator of early disease and correlates with physiologic fibrofatty replacement of heart muscle tissue in DMD¹². However, LGE might also be considered a relatively late 98 99 finding as it can only be detected when a substantial portion of the myocardium has 100 been affected. Cardiac strain measures the relative deformation of the myocardium 101 throughout the cardiac cycle with end diastole assumed to be the reference state. Strain has shown promise as an early indicator of disease,⁸ but is not currently used 102 103 extensively in clinical decision making. 104

We have recently developed novel methods for assessing regional strain using stacked short-axis CMR images¹³. This innovative approach involves the utilization of a method for quantifying 4D (3D+time) cardiovascular magnetic resonance (CMR) regional strain. With this approach, we hypothesize DMD patient groups can be differentiated based on their strain patterns to predict the rate of CMP progression, contributing to a deeper understanding of the disease, paving the way for more targeted interventions, and eventually improving patient outcomes.

112

113 Methods:

114 Patient Population:

In this study, we analyzed data from patients with a range of DMD-associated CMP from an observational study approved by the Vanderbilt Institutional Review Board. All participants adhered to approved protocols and provided their consent or assent. The original study enrolled DMD CMP patients who had received a phenotypic diagnosis of DMD, subsequently confirmed through genetic testing or muscle biopsy. As possible, each patient in the study had three consecutive CMR scans each about 12 months

apart (12.3±0.8 months; mean±SD). Our study excluded patients with diagnoses other
 than DMD and those with inadequate assessment or non-diagnostic results for LGE.

123

124 Patient Stratification:

125 DMD patients presented with a range of CMP severity at the initial visit: 12 with reduced 126 LVEF of <55% (30% of total) and 26 with LGE (65% of total). We initially categorized 127 patient CMP into Stage A (LVEF 255%, no LGE; n=14), Stage B (LVEF 255%, with LGE; n=14), Stage C (40%<LVEF<55%, with LGE; n=9), or Stage D (LVEF<40%, with LGE; 128 129 n=3) based on the 2022 AHA's guideline for the management of heart failure¹⁴. We also 130 grouped patients based on initial visit LVEF and progression after two years. We chose 131 to group patients this way in an effort to model the natural history differences between 132 DMD patients with normal LVEF (≥55%) vs. those with abnormal LVEF (<55%). The 133 patient groups were further categorized by decrease in LVEF two years following the 134 initial visit as follows: normal, slow progression: initial LVEF≥55%, +2 years △LVEF%≤5 135 (n=12), normal, fast progression: initial LVEF \geq 55%, +2 years Δ LVEF%>5 (n=15), 136 abnormal, slow progression: initial LVEF<55% +2 years Δ LVEF% \leq 5 (n=8), abnormal, 137 fast progression: initial LVEF<55%, +2 years Δ LVEF%>5 (n=4). One patient was

- 138 excluded due to poor image quality.
- 139

140 *Image Acquisition:*

We obtained CMR images using a 1.5 Tesla scanner (Avanto or Avanto Fit, Siemens 141 Healthineers, Erlangen, Germany) as described previously^{13, 15}. Briefly, we acquired 142 balanced steady-state free precession (bSSFP) cine images in the 4-chamber, 3-143 144 chamber, 2-chamber, and a short-axis stack. Typical imaging parameters were 6-8 mm 145 thickness, 20-25 images per cardiac cycle with 11-17 short axis cine slices per patient. 146 LGE imaging included single-shot phase-sensitive inversion recovery bSSFP imaging 147 with an inversion time of 300 ms and segmented inversion recovery turboFLASH 148 sequences with optimized inversion recovery to null myocardial signal.

All images were analyzed by an image analyst with over 5 years of experience and all

analyses were verified by a pediatric cardiologist with more than 10 years of experience.

151 Ventricular function and volumes were calculated using Medis QMass (MedisSuite 2.1,

Medis, Leiden, The Netherlands). The presence or absence of LGE was qualitatively
 assessed and localized using the standard 17-segment model¹⁶.

- 154
- 155 Strain Analysis:

156 We performed 4D CMR strain analysis using a custom-built graphical user interface in MATLAB (R2022b, Mathworks, Natick, Massachussetts, USA) as described 157 previouslv¹³. In short, we first compiled short-axis cine CMR DICOM images into a 158 159 volumetric data viewer that could reconstruct the axial, sagittal, and coronal planes of 160 the heart. For each 4D image, the user then identified a centerline along the longitudinal 161 axis of the left ventricle and tracked apical and basal movement along this axis. 162 Following this step, four equally spaced parallel short axis slices along this axis were 163 identified. For each slice, the user tracked the movement of the endocardial and 164 epicardial borders throughout the cardiac cycle in both the short axis and in one of three planes perpendicular to the short axis that corresponded approximately to conventional 165 166 long-axis, two-chamber, and four-chamber views. This method amounts to tracking a 167 structured set of 48 points throughout the myocardium in addition to basal and apical 168 movement across a representative cardiac cycle. Following this step, we used spatial 169 and temporal spline interpolation to create a dynamic 3D deformable mesh representing the left ventricle^{13, 17, 18}. We then used this mesh to derive the following components of 170 strain throughout the entire 3D mesh: circumferential strain (E_{cc}), longitudinal strain (E_{\parallel}), 171 radial strain (E_{rr}), and surface area strain (E_a) in a Lagrangian reference frame as 172 described previously¹³. From each strain component, we also derived regional average 173 174 strain rates by measuring the slope of the strain curve in systole, early diastole, and late diastole, as described previously^{13, 19}. 175

176

177 Statistical Analysis:

We assessed the distribution for each metric using a Shapiro-Wilk test (p < 0.05). Nonparametric statistics were used for data sets not following a normal distribution. When comparing two groups, we used t-test or Mann-Whitney test for parametric and nonparametric data respectively, and used the Holm-Sidak method for adjusting the p-value for multiple comparisons. When comparing multiple groups, we used an ANOVA with


- 183 the Tukey-Kramer method for multiple comparisons for parametric data or the Kruskal-
- 184 Wallis test and Dunn's multiple comparison test for non-parametric data. For comparing
- 185 categorical variables (i.e. LGE presence) we used a Fisher Exact Test.
- 186

187 **Results:**

- 188 Over the study period, we included 115 CMR studies in our analysis from n=40 patients.
- 189 We imaged all of these patients using gadolinium contrast. LVEF, LGE status,
- 190 demographic and clinical parameters in addition to other imaging variables were
- 191 collected as outlined below in Table 1.
- 192
- 193 **Table 1:** Clinical information obtained over three annual visits from patients with
- 194 Duchenne muscular dystrophy-associated cardiomyopathy (DMD CMP).

| | Visit 1 | Visit 2 | Visit 3 |
|-----------------------------|------------------|------------------|------------------|
| | (n=40) | (n=38) | (n=36) |
| Age (years) | 12.4 [10.5-16.6] | 12.8 [11.5-17.0] | 13.7 [12.5-17.0] |
| Height (cm) | 146 [127-163] | 152 [142-161] | 152 [142-163] |
| Weight (kg) | 47.2 [36.4-65.0] | 53.6 [39.5-69.9] | 58.5 [43.2-72.8] |
| BSA (m^2) | 1.4 [1.2-1.7] | 1.5 [1.3-1.8] | 1.6 [1.3-1.8] |
| HR (BPM) | 103 [92-116] | 97 [89-105] | 100 [89-111] |
| Systolic (mmHg) | 115 [107-120] | 117 [106-123] | 115 [105-120] |
| Diastolic (mmHg) | 66 [61-74] | 68 [63-74] | 69 [59-76] |
| LVEF (%) | 59 [51-62] | 57 [49-59] | 55 [49-58] |
| LVEDVI (ml/m ²) | 59 [54-70] | 61 [52-68] | 65 [57-71] |
| LVESVI (ml/m ²) | 24 [20-34] | 26 [22-33] | 29 [25-34] |
| CO (L/min) | 4.9 [4.0-5.8] | 4.7 [4.1-5.3] | 5.1 [4.0-6.0] |
| LVEF<55%, n(%) | 12 (30) | 16 (42) | 18 (50) |
| +LGE, n(%) | 26 (65) | 29 (76) | 34 (94) |
| Stage A, n(%) | 14 (35) | 9 (24) | 2 (6) |
| Stage B, n(%) | 14 (35) | 13 (34) | 16 (44) |
| Stage C, n(%) | 9 (22.5) | 14 (37) | 16 (44) |
| Stage D, n(%) | 3 (7.5) | 2 (5) | 2 (6) |

BSA, body surface area; HR, heart rate; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end diastolic volume indexed to BSA; LVESVI, left ventricular end systolic volume indexed to BSA; LVCO, left ventricular cardiac output; LGE, late gadolinium enhancement. Stage A, LVEF>55%, LGE(-); Stage B, LVEF>55%, LGE(+); Stage C, 40%<LVEF<55%, LGE(+); Stage D, LVEF<40%, LGE(+). Values reported as median [interquartile range] or as number of subjects (percentage of group)—n(%).



196

197 **Figure 1:** DMD CMP heart failure staging and cohort overview. A) Heart failure staging

198 criteria. B) Stacked column chart depicting patient groups at visit 1 (initial visit), visit 2

199 (+1 year), and visit 3 (+2 years). C) Sankey diagram depicting heart failure stages

200 across visits.

201

202 Late Gadolinium Enhancement:

203 We measured the presence of LGE in each patient and found that the percentage of

204 patients with LGE increased over time from 65% (n=26) at the initial visit to 76% (n=29)


at +1 year and 94% (n=34) at +2 years. Additionally, the highest number of patients had

206 findings of LGE in the basal and lateral segments of the heart with 81% (n=29) of

207 patients having LGE in the basal inferolateral segment of the heart and 78% (n=28) in

208 the basal anterolateral segment of the heart (Figure 2B).





- 210 **Figure 2:** LGE presence increases over time in DMD, particularly in the basal and
- 211 lateral regions of the heart. A) 17-segment polar plot map. B) Intensity plot depicting the
- 212 percentage of patients with LGE findings for visit 1 (V1; initial visit; n=40), visit 2 (V2; +1
- 213 year; n=38), and visit 3 (V3; +2 years; n=36), with lighter shading depicting a higher
- 214 percentage of LGE. C) 17-segment plot depicting the percentage of the patient cohort
- with LGE based on region, with lighter shading depicting a higher percentage of LGE.
- 216
- 217 Strain Mapping and Progression:

- 218 We calculated circumferential (E_{cc}), longitudinal (E_{II}), radial (E_{rr}), and surface area strain
- (E_a) from 3D+time CMR images for each patient at the initial, second, and third visit. We
- 220 plotted E_{cc} and E_{II} using a Cartesian color map where the region of the heart is
- displayed on the y-axis and relative time in the cardiac cycle is depicted on the x-axis
- 222 (Figure 3 A-D). We also plotted E_{rr} and E_a at peak systole using a polar plot (Figure 3 A-
- D). For many patients, we found striking qualitative differences in strain maps between
- visits indicating an overall decrease in strain magnitude over time (Figure 3).




Figure 3: Regional 4D CMR strain metrics change over time in an individual patient. A)

226 Graphical depiction of strain component calculation and graphical representation for

227 circumferential (E_{cc}), longitudinal (E_{II}), radial (E_{rr}), and surface area strain (E_a). B,C,D)

- 228 Strain maps for an individual patient at the initial visit (B), 2nd visit: +1 year (C), and 3rd
- 229 visit: +2 years (D).

- 231 Using the same strain mapping conventions, we also plotted composite group-averaged
- strain maps to evaluate averaged strain differences and patterns between groups with
- 233 varying CMP severity (Figure 4). While there were no statistical difference between
- 234 LVEF for Stage A (61.6±3.1%; mean±SD; n=14) and Stage B (61.5±5.2%; n=14;
- 235 *p*=0.93), there were significant differences in global peak strain values between Stage A
- and Stage B. These differences included E_{\parallel} (-10.9±1.5, -8.6±1.4, *p*=0.002), E_{rr} (27±9.5,
- 237 18.2 \pm 6.3, *p*=0.038), and E_a (-31.9 \pm 3.4, -28 \pm 3.9, *p*=0.037). There were no significant
- differences in global peak strain between Stage B and Stage C, though differences
- approached significance for basal E_a peak strain (-25.2±2.8, -22.4±1.8, *p*=0.057). There
- were, however, significant differences in global peak strain between Stage C and Stage
- 241 D for E_{cc} (-9.6±1.7, -5.9±2.4, *p*=0.017) and E_a (-24.9±1.9, -16.2±5.5, *p*=0.004).
- Additional regional peak differences are shown in Supplemental Table 1.
- 243




Figure 4: Regional 4D CMR strain metrics can differentiate between heart failure


- stages. A,B,C,D) Initial visit, group-averaged circumferential (E_{cc}), longitudinal (E_{II}),
- radial (E_{rr}), and surface area strain (E_a) maps for Stage A (LVEF≥55%, no LGE), B
- 247 (LVEF≥55%, with LGE), C (40%<LVEF<55%, with LGE), or D (LVEF<40%, with LGE).
- 248 E,F,G,H) Global peak systolic strain values comparing heart failure stages at the initial
- visit for $E_{cc}(E)$, $E_{\parallel}(F)$, $E_{rr}(G)$, and $E_a(H)$. **p*<0.05 adjusted for multiple comparisons.
- 250

251 Strain Mapping and Progression

252 We further examined strain differences based on the progression of CMP from the initial

- visit as measured by the change in LVEF. As described in the methods, we grouped our
- patients into normal (LVEF≥55%) and abnormal (LVEF<55%) groups and further into
- slow (+2 years: △LVEF%≤5) or fast (+2 years: △LVEF%>5) progressors based on
- 256 individual decrease in LVEF (Figure 5A). We were particularly interested in
- 257 distinguishing progression differences between individuals with baseline normal function
- and those with baseline abnormal function. We found that at the initial visit, traditional
- 259 functional metrics did not show statistical differences in the normal cohort between slow
- and fast progression including LVEF (p>0.99), age (p>0.99), and LGE status (p=0.704;
- Figure 5B,C). We saw similar trends in the abnormal cohort between slow and fast
- progression groups for LVEF (*p*=0.70) and age (*p*>0.99; Figure 5B,C). We did, however,
- 263 note distinct qualitative differences in initial visit group-averaged strain maps between
- each progression group (Figure 5D-G) as well as in strain maps from representative

265 individuals from each group (Supplemental Figures 1-4).



266

Figure 5: Standard metrics cannot differentiate between fast and slow progression;

268 however, group-averaged strain maps reveal distinct qualitative differences between

269 groups. A) Progression group descriptions for normal, slow progression (initial

270 LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progression (initial LVEF \geq 55% +2 years

 $\Delta LVEF\% > 5$), abnormal, slow progression (initial LVEF<55% +2 years $\Delta LVEF\% \le 5$), and

abnormal, fast progression (initial LVEF<55% +2 years △LVEF%>5). B,C) LVEF

comparison (B) and age comparison (C) at the initial visit between groups. D,E,F,G)


- Group averaged strain plots at the initial visit. **p*<0.05 adjusted for multiple
- comparisons.
- 276

277 We also found some distinct quantitative differences in regional strain metrics between

groups (Supplemental Tables 2 and 3). Patients with initially normal LVEF and fast

279 progression had decreased peak systolic strain magnitude (Figure 6A) in the basal

280 region only for E_{cc} (*p*=0.002), E_{rr} (*p*=0.001), and E_a (*p*=0.003; Figure 6B,C;



- 282 differences in the normal cohort between fast and slow progression for systolic strain
- rate. However, the fast progressors had decreased early diastolic strain rate magnitude
- for basal E_{rr} (p=0.001) and global E_{rr} (p=0.044). There were also differences in late
- diastolic strain rate for E_{cc} in the basal (p<0.001), mid-LV (p=0.026), and global
- (p=0.026) regions (Figure 6F) and for E_a in the basal (p=0.001), mid-LV (p=0.042), and
- global (p=0.042) regions (Figure 6G). Between fast and slow progressors in the
- abnormal cohort, there were no significant differences in peak systolic strain or systolic
- strain rate, however, there was a difference in early diastolic strain rate for E_{\parallel} in the
- anterior segment (p=0.048; Supplemental Table 3). Additionally, late diastolic strain rate
- magnitude was decreased in fast progressors for E_{cc} in the basal (p=0.045) and mid-LV
- 292 (p=0.031) regions (Figure 6H) and for E_a in the basal (p=0.018), mid-LV (p=0.018)
- regions, and globally (*p*=0.018; Figure 6I).




Figure 6: 4D CMR regional peak strain and late diastolic strain rate can differentiate between slow and fast progression in both subclinical and clinical CMP. A) Strain curve depiction. B,C,D,E) Initial visit peak systolic strain showing differences between normal, slow progressors (initial LVEF \geq 55% +2 years Δ LVEF% \leq 5) and normal, fast progressors

(initial LVEF \geq 55% +2 years Δ LVEF%>5) for E_{cc} (B) and E_a (C). Peak strain differences between abnormal, slow progressors (initial LVEF<55% +2 years Δ LVEF% \leq 5) and abnormal, fast progressors (initial LVEF<55% +2 years Δ LVEF%>5) are shown for E_{cc} (D) and E_a (E). F,G,H,I) Late diastolic strain rate differences are shown between fast and slow progression in the normal cohort for E_{cc} (F) and E_a (G) and between fast and slow progression in the abnormal cohort for E_{cc} (H) and E_a (I). **p*<0.05 adjusted for multiple comparisons.

- 306
- 307

308 **Discussion:**

309 We report here that regional 4D CMR strain parameters are useful for stratifying 310 patients based on both disease status and risk of progression. In this study, we used 311 diagnostic CMR along with regional LGE to classify and phenotype a cohort of DMD 312 patients followed annually over three visits. Further, we utilized a novel 4D CMR 313 reconstruction and feature-tracking approach to derive and assess regional strain 314 parameters. Finally, we used these strain-based parameters to evaluate differences in 315 the rate of progression between patient groups prior to changes in LVEF or LGE. These 316 findings and the metrics described here can be used to better describe the progression 317 of CMP in a cohort of DMD patients followed longitudinally over time. This information is 318 vital for improving the understanding and characteristics of this disease and justifies an 319 increased need for larger, multi-center natural history studies in this patient population. 320 It remains to be seen if 4D CMR strain parameters are modifiable or respond to 321 treatment to delay CMP progression.

322

323 Late Gadolinium Enhancement (LGE)

LGE is an important and early finding In DMD indicating the progression of CMP and fibrofatty replacement of cardiac muscle. In our cohort which had a wide range of CMP severity, we found that LGE presence increased over time from the initial and that the presence of LGE preceded patients having an LVEF<55%, a finding similar to other studies²⁰. We also found that the greatest proportion of patients developed LGE in the basal and lateral portions of the left ventricle (Figure 2). At the initial visit, 25 out of the

26 patients with LGE had findings of LGE in the basal inferolateral region. There was
also the greatest increase in the proportion of patients with LGE in this region. For
example, there was an increase in the proportion of patients with LGE from 63% (n=25)
to 81% (n=29) in the basal anterolateral region throughout the study. These findings are
consistent with other studies that have shown regional differences in LGE presence in
DMD patients^{15, 21} and offer further evidence for the importance of regional assessment.

This regional variation in LGE accumulation might be partially explained by the differences in stress within the left ventricle governed by the Law of Laplace. This law describes how such factors as pressure, local curvature, and increased myocardial thickness contribute to stress which is relatively higher in the basal segments of the heart^{22, 23}. Thus, LGE accumulation in the base of the heart suggests strain parameters in the basal region may be useful for differentiating disease severity and progression.

344 Heart Failure Staging

345 In previous work, we showed how 4D CMR regional strain parameters could strongly differentiate between DMD and healthy control patients¹³. In this study, we 346 347 demonstrated that global peak strain could also differentiate between patients in Stage 348 A (LVEF≥55%, no LGE) and Stage B (LVEF≥55% with LGE; Figure 4). This is an 349 important finding because traditional metrics, such as LVEF, do not differentiate 350 between these groups. This suggests that 3D+time strain metrics may be a useful non-351 contrast method for identifying the presence of LGE and/or fibrosis. Non-contrast 352 methods to characterize CMP onset and progression could decrease scan time, reduce 353 the need for contrast (LGE), and expand the number of DMD patients who could undergo CMR¹⁵. In summary, these data suggest that 4D CMR strain might be used for 354 355 stratifying patient risk, increasing access to imaging, and guiding clinical management. 356

357 Strain Mapping and Progression

358 One of the most clinically challenging aspects of DMD CMP care is understanding the

- risk profile of patients. By examining DMD patients with a range of CMP severity, we
- 360 were able to identify patients who were more likely to experience rapid progression over

361 the course of two years. We also distinguished between patient groups who initially had 362 subclinical CMP (LVEF≥55%) versus those who had evidence of CMP (LVEF<55%). 363 We made this initial distinction as it represents two clinically distinct groups with differences in their short-term natural history that might be of interest to clinical 364 365 providers. Interestingly, we found that conventional metrics of LVEF, age, or LGE status could not differentiate between fast or slow progression in overt or subclinical CMP. We 366 367 did find, however, that regional 4D CMR strain parameters could make this distinction 368 (Figure 6, Supplemental Table 2,3), suggesting this approach may be better for 369 detecting early changes in cardiac function.

370

371 The strongest differentiators for CMP progression in patients with normal function were peak systolic basal E_{cc}, E_a, and E_{rr} strain, early diastolic basal E_{rr} strain rate, late 372 373 diastolic basal E_{cc} rate, and late diastolic basal E_a strain rate. The strongest 374 differentiators for CMP progression in patients with abnormal function were regional late 375 diastolic E_{cc} and E_a strain rates. These results indicate that, just as we observed in the 376 LGE pattern, changes in the kinematics of the basal region of the heart may be an early 377 indication of disease severity and potential for progression. These results are consistent 378 with the findings of other studies using 3D strain in DMD. Siddigui et al. showed 379 previously that for DMD patients with an initial LVEF≥55% reductions in global 3D E_{cc} and E_{rr} could be indicative of a >10% decline in LVEF up to 32 months later²⁴. 380 381

382 Another important finding of this study is the additive value of using regional diastolic 383 strain rate as a metric for differentiating patient progression. Others have shown that abnormalities in diastolic function may be an early indication of CMP onset²⁵. To our 384 385 knowledge, this is the first study that describes the use of regional diastolic strain rate 386 from 4D CMR as an early metric for CMP progression in DMD. Impaired diastolic 387 relaxation in these patients may be an early sign of ventricular stiffening from fibrofatty 388 replacement of cardiomyocytes and impaired kinematics. Despite this progress, further 389 focus and study on both systolic and diastolic strain-based metrics in this population is 390 merited.

392 Strengths and Limitations

393 This study has several strengths and limitations. The analysis currently requires a post-394 processing approach using a custom image analysis code for 4D CMR analysis. 395 Incorporation of this method or similar approach in combination with emerging artificial 396 intelligence (AI) assisted feature tracking would allow this kind of analysis to be 397 automated and performed within a reasonable clinical image analysis workflow. 398 Additionally, several of the short-axis stacks were shifted relative to others in the 3D 399 stack due to breathing and motion artifacts. This could have been partially due to the 400 young age of the patients, who may be unable to lie still during imaging for long periods 401 of time. Using contextual information from other slices, we can still evaluate these 402 images, but there was one dataset that we were unable to reconstruct in three dimensions due to these artifacts. Al-assisted motion correction and CMR sequences 403 404 that do not rely on breath-holding could overcome these artifacts in the future. Further, 405 this is a cohort followed over three annual imaging sessions with a relatively wide range 406 of CMP severity. Though our sample size is relatively high for a rare disease, the 407 smaller sample size limits the power of our study, in particular when performing 408 subgroup analysis. Because of the limited sample size, we also did not adjust for 409 medication effects on our cohort, though all patients were treated at the same clinic with 410 standard of care and a proactive treatment approach. Therefore, the range and 411 differences in progression in our cohort are likely very similar to what a clinician would 412 be seeing in practice. Future studies with larger group sizes should adjudicate treatment 413 affects.

414

415 Strengths of this study include the longitudinal follow-up of patients, comprehensive 416 regional 4D CMR strain analysis, and the study design allowing us to evaluate the rate 417 of progression among our patients. The longitudinal analysis of patients allowed us to 418 evaluate both individual patient and group averaged progression as well as changes 419 over time. Additionally, our novel 4D CMR feature tracking software allowed us to 420 assess not only global function but also detailed spatial and temporal information for 421 each strain component. Here we also describe the use and value of surface area strain 422 (E_a) which is a parameter unique to gated 3D imaging as it is a measure of 3D surface

- 423 deformation. To our knowledge, this is the first description of 4D CMR strain parameters
- 424 for differentiation of disease severity and both subclinical and clinical rates of
- 425 progression.
- 426
- 427 Conclusion
- In this study, we described the value of 4D CMR imaging metrics for differentiating both
- 429 CMP disease severity and rate of progression. We showed that basal region peak strain
- 430 and late diastolic strain rate for E_{cc} and E_a were correlated with the rate of cardiac
- disease progression in DMD patients. Further studies assessing the natural history and
- 432 progression of DMD CMP using these techniques could help assess individual patient
- 433 risk profiles and guide treatment to improve clinical outcomes.
- 434


435 Acknowledgments:

- The authors acknowledge senior imaging research specialist Kristen George-Durrett for
- 437 her help and expertise in image data management.
- 438

439 **Sources of Funding:**


- 440 Research reported in this publication was supported by the Ackerman/Nicholoff Family
- 441 (L. Markham), Fighting Duchenne Foundation and the Fight DMD/Jonah & Emory
- 442 Discovery Grant (J. Soslow), the Food and Drug Administration Orphan Products Grant
- 443 R01FD006649 (J. Soslow), the National Center for Research Resources, Grant UL1
- 444 RR024975-01, and is now at the National Center for Advancing Translational Sciences,
- 445 Grant 2 UL1 TR000445-06 (G. Bernard), and by the National Heart, Lung, and Blood
- 446 Institute of the National Institutes of Health under Award Number F30HL162452 (C.
- 447 Earl), K23HL123938 (J. Soslow), and R56HL141248 (J. Soslow). This publication was
- 448 also made possible with support from Grant Number, UL1TR002529 (S. Moe and S.
- 449 Wiehe, co-PIs) from the National Institutes of Health, National Center for Advancing

- 450 Translational Sciences, Clinical and Translational Sciences Award (C. Earl), and the
- 451 Leslie A. Geddes Endowment at Purdue University (C. Goergen). Engineering in
- 452 Medicine Pilot Fund between Purdue University College of Engineering and Indiana
- 453 University School of Medicine (L. Markham, C. Goergen, C. Earl). The content is solely
- the responsibility of the authors and does not necessarily represent the official views of
- 455 the National Institutes of Health.
- 456
- 457 **Disclosures:**
- 458 The authors have no disclosures related to the publication of this work.
- 459



460 **Supplemental Tables and Figures:**


- 461
- 462 Supplemental Figure 1: Circumferential strain (E_{cc}) progression. A,B,C,D) E_{cc}
- 463 Cartesian maps showing differences between a normal, slow progressor (A; initial
- LVEF≥55% +2 years △LVEF%≤5), normal, fast progressor (B; initial LVEF≥55% +2
- 465 years Δ LVEF%>5), abnormal, slow progressor (C; initial LVEF<55% +2 years
- 466 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF<55%, +2 years Δ LVEF%>5)
- 467 over the course of three annual visits.
- 468



469

Supplemental Figure 2: Longitudinal strain (E_{II}) progression. A,B,C,D) E_{II} Cartesian maps showing differences between a normal, slow progressor (A; initial LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progressor (B; initial LVEF \geq 55% +2 years Δ LVEF%>5), abnormal, slow progressor (C; initial LVEF<55% +2 years Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF<55%, +2 years Δ LVEF%>5) over the course of three annual visits.

- 477
- 478
- 479
- 480





481

482 **Supplemental Figure 3:** Radial strain (E_{rr}) progression. A,B,C,D) E_{rr} polar strain maps

483 at peak systole showing differences between a normal, slow progressor (A; initial

- 484 LVEF \geq 55% +2 years Δ LVEF \ll 5), normal, fast progressor (B; initial LVEF \geq 55% +2
- 485 years Δ LVEF%>5), abnormal, slow progressor (C; initial LVEF<55% +2 years
- 486 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF<55%, +2 years Δ LVEF%>5)
- 487 over the course of three annual visits.
- 488
- 489
- 490
- 491





years Δ LVEF%>5), abnormal, slow progressor (C; initial LVEF<55% +2 years

 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF<55%, +2 years Δ LVEF%>5)

over the course of three annual visits.

503 **Supplemental Table 1**: Regional 4D CMR peak systolic strain differences between

504 heart failure stages.

| | | | Peak | p value | | | | | | | | |
|-------------------|------------------------------------|---------------------------|----------------------------|----------------------|------------------------|----------------------|--------|------------------|--------|-------|--------|--------|
| | Strain | Region | Stage A | Stage B | Stage C | Stage D | A-B | A-C | A-D | B-C | B-D | C-D |
| | | Base | -20±1.3 | -18.3±2.9 | -16.1±2.1 | -10±3.9 | 0.292 | 0.003* | 0.000* | 0.145 | 0.000* | 0.002* |
| | Circumferential E _{cc} | Mid | | | -18.2±2.4 | | | | | | | |
| | LCC | Apex Global | -27.4±5.9 -23.2±3 | | -20.2±3.2 -18.2±1.7 | | | 0.037* 0.006* | | | | |
| | | Anterior FW | -23.2±3 | -20.7±4 | -18.2±1.7 | -11.1±4.5 | 0.214 | 0.006* | 0.000* | 0.315 | 0.000* | 0.013* |
| | | Anterior Anterior S | -11.2±2.1 -9.9±1.7 | -9.3±2.3 -7.6±1.4 | -9.4±1.2 -7.6±1.8 | -5.7±2.2 -6.2±1.1 | | | | | | |
| | Longitudinal E _ແ | Posterior S | -9.8±1.8 | -7.7±1.3 | -7.9±1.7 | -6.7±1.2 | 0.009' | 0.032* | 0.017* | 0.997 | 0.718 | 0.662 |
| | | Posterior Posterior FW | -11.2±1.9 | -8.6±1.6 | -8.6±1.6 | -6.5±2.6 -6.1±2.8 | | | | | | |
| | | Global | -11.3 ± 1.2 -10.9±1.5 | -9.3±1.5 -8.6±1.4 | -8.5±1.3 -8.6±1.2 | -6.1±2.8 | | | | | | |
| | | Base | 27.6±10.1 | 24.8±10.7 | 18.1±10.5 | 7.2±4.1 | 0.897 | 0.151 | 0.018* | 0.424 | 0.049* | 0.393 |
| | Radial | Mid | | | 21.3±10.8 | | | | | | | |
| | Err | Apex Global | 21.9±12.7 27±9.5 | 9.6±4.2 18.2±6.3 | 13.2±7.9 18.1±8.3 | 5.7±5.7 7.2±6.9 | | | | | | |
| | | Base | | | -22.4±1.8 | | | | | | | |
| | Surface Area | Mid | -30.7±3.6 | | -24.2±2.4 | | | | | | | |
| | Ea | Apex Global | -39.5±7.4 -31.9±3.4 | -33.7±8.3 | -29.4±5 -24.9±1.9 | | | | | | | 0.137 |
| 505 506 507 | Stage A (LVEF LGE); Stage D | | | | | | | | | | 5%, w | ith |
| 508 | | | | | | | | | | | | |
| 509 | | | | | | | | | | | | |
| 510 | | | | | | | | | | | | |
| 511 | | | | | | | | | | | | |
| 512 | | | | | | | | | | | | |
| 513 | | | | | | | | | | | | |
| 514 | | | | | | | | | | | | |
| 515 | | | | | | | | | | | | |
| 516 | | | | | | | | | | | | |
| 517 | | | | | | | | | | | | |
| 518 | | | | | | | | | | | | |

Supplemental Table 2: Regional strain differences between cardiomyopathy groups

521 with normal LVEF:

| Strain | Region | Peak Systolic S | | lic Strain R | c Strain Rate Early Diastolic Strain Rate | | | train | Late Diastolic Strain Rate | | | | |
|-----------------|--------------|-----------------|-----------|--------------|--|-----------|-------|-----------|-------------------------------|--------|-----------|-----------|-------|
| | | Group 1 | Group 2 | р | Group 1 | Group 2 | р | Group 1 | Group 2 | р | Group 1 | Group 2 | р |
| | Base | -20.5±1.8 | -17.5±2.1 | 0.002* | -1.19±0.3 | -1.04±0.1 | 0.348 | 1.05±0.3 | 0.85±0.2 | 0.193 | 1.08±0.2 | 0.71±0.2 | 0.000 |
| Circumferential | Mid | -21.3±3.4 | -20.4±3.2 | 0.745 | -1.36±0.5 | -1.24±0.2 | 0.365 | 1.16±0.4 | 0.99±0.2 | 0.23 | 1.11±0.3 | 0.84±0.2 | 0.026 |
| Ecc | Apex | -25.9±6.9 | -25±6.4 | 0.745 | -1.78±0.6 | -1.54±0.4 | 0.364 | 1.57±0.6 | 1.32±0.4 | 0.23 | 1.35±0.6 | 1.03±0.4 | 0.13 |
| | Global | -22.5±3.8 | -21±3.3 | 0.629 | -1.51±0.3 | -1.25±0.2 | 0.075 | 1.25±0.4 | 1.03±0.2 | 0.208 | 1.14±0.3 | 0.87±0.2 | 0.02 |
| | Anterior FW | -10.2±1.8 | -10.9±2 | 0.956 | -0.57±0.1 | -0.62±0.1 | 0.836 | 0.48±0.1 | 0.5±0.1 | 0.997 | 0.46±0.1 | 0.4±0.1 | 0.77 |
| | Anterior | -9.7±2.7 | -10.7±2.2 | 0.929 | -0.56±0.2 | -0.61±0.1 | 0.945 | 0.45±0.1 | 0.45±0.1 | 0.999 | 0.4±0.1 | 0.42±0.1 | 0.97 |
| Longitudinal | Anterior S | -8.4±2.1 | -8.9±1.8 | 0.979 | -0.47±0.1 | -0.5±0.1 | 0.945 | 0.36±0.1 | 0.37±0.1 | 0.999 | 0.37±0.1 | 0.35±0.1 | 0.97 |
| E | Posterior S | -8.5±1.8 | -8.8±1.9 | 0.979 | -0.48±0.1 | -0.51±0.1 | 0.945 | 0.37±0.1 | 0.36±0.1 | 0.999 | 0.37±0.1 | 0.34±0.1 | 0.97 |
| -11 | Posterior | -9.7±2.1 | -9.9±2.2 | 0.979 | -0.53±0.1 | -0.58±0.2 | 0.945 | 0.45±0.1 | 0.42±0.1 | 0.959 | 0.39±0.1 | 0.38±0.1 | 0.97 |
| | Posterior FW | -10.3±1.8 | -10.3±1.6 | 0.979 | -0.58±0.1 | -0.58±0.1 | 0.945 | 0.5±0.1 | 0.48±0.1 | 0.999 | 0.46±0.1 | 0.38±0.1 | 0.30 |
| | Global | -9.5±1.9 | -9.9±1.7 | 0.979 | -0.53±0.1 | -0.57±0.1 | 0.945 | 0.43±0.1 | 0.42±0.1 | 0.999 | 0.41±0.1 | 0.37±0.1 | 0.92 |
| | Base | 34.6±10.2 | 20.2±6.9 | 0.001* | 1.77±0.9 | 1.03±0.5 | 0.054 | -2.65±0.7 | -1.5±0.7 | 0.001* | -1.29±1.1 | -0.63±0.5 | 0.20 |
| Radial | Mid | 23.2±7.5 | 22.3±15 | 0.979 | 1.02±0.4 | 1.38±1.2 | 0.695 | -1.96±0.6 | -1.48±1 | 0.256 | -0.58±0.8 | -0.93±0.9 | 0.67 |
| Err | Apex | 15.6±9.2 | 15±12.7 | 0.979 | 0.75±0.8 | 0.86±0.8 | 0.88 | -1.31±0.8 | -1.12±1 | 0.596 | -0.5±0.8 | -0.58±1.1 | 0.93 |
| | Global | 25.5±6.6 | 19.7±10.5 | 0.286 | 1.23±0.5 | 1.12±0.7 | 0.88 | -2.06±0.4 | -1.4±0.8 | 0.044* | -0.82±0.8 | -0.73±0.7 | 0.93 |
| | Base | -28±1.8 | -24.7±2.4 | 0.003* | -1.63±0.2 | -1.46±0.2 | 0.117 | 1.39±0.2 | 1.19±0.2 | 0.131 | 1.35±0.3 | 0.99±0.2 | 0.00 |
| Surface Area | Mid | -29.2±4.1 | -27.6±3.8 | 0.509 | -1.84±0.3 | -1.66±0.2 | 0.199 | 1.47±0.4 | 1.29±0.2 | 0.222 | 1.4±0.3 | 1.11±0.2 | 0.04 |
| Ea | Apex | -36.6±8.6 | -35.8±7.7 | 0.802 | -2.46±0.7 | -2.21±0.4 | 0.299 | 2.16±0.8 | 1.8±0.4 | 0.222 | 1.75±0.6 | 1.58±0.5 | 0.43 |
| | Global | -30.6±4.1 | -28.6±3.5 | 0.452 | -1.92±0.3 | -1.72±0.2 | 0.199 | 1.61±0.4 | 1.38±0.2 | 0.152 | 1.47±0.3 | 1.18±0.2 | 0.04 |

522 Group 1: normal, slow progression (initial LVEF \geq 55%, +2 years Δ LVEF% \leq 5) and Group 2: normal, fast 523 progression (initial LVEF \geq 55%, +2 years Δ LVEF% \leq 5); *p<0.05, adjusted for multiple comparisons.

540

541 **Supplemental Table 3:** Regional strain differences between DMD cardiomyopathy

542 groups with abnormal LVEF

| Strain | Region | Peak | | Systolic Strain Rate | | | Early Diastolic Strain Rate | | | Late Diastolic Strain Rate | | | |
|------------------------------------|---|--|--|--------------------------------------|---|---|----------------------------------|--|--|-------------------------------|--|----------------------------------|---|
| | | Group 3 | Group 4 | р | Group 3 | Group 4 | р | Group 3 | Group 4 | р | Group 3 | Group 4 | р |
| | Base | -15.9±2.4 | -11.8±4.6 | 0.185 | -0.88±0.2 | -0.78±0.4 | 0.547 | 0.88±0.2 | 0.57±0.2 | 0.096 | 0.68±0.2 | 0.4±0.2 | 0.045* |
| Circumferential E _{cc} | Mid Apex Global | -19.4±3.4 | -13±5.6 -15.6±7.1 -13.5±5.7 | 0.233 | -1.16±0.3 | -0.88±0.4 | 0.385 | | 0.7±0.3 0.73±0.4 0.66±0.3 | 0.258 | | 0.48±0.1 0.6±0.3 0.48±0.2 | 0.031* 0.188 0.053 |
| Longitudinal E _{ll} | Anterior FW Anterior Anterior S Posterior S Posterior Posterior FW Global | -9.1±1.9 -9.2±1.3 -7.2±1.6 -7.6±1.5 -8.3±1.8 -8.1±1.5 -8.2±1.2 | -7.1±3.1 -7.5±2.1 -7.4±2 -7.6±2.7 -7.6±2.9 | 0.57 0.97 0.97 0.97 0.97 | -0.49±0.1 -0.48±0.1 -0.39±0.1 -0.42±0.1 -0.45±0.1 -0.42±0.1 -0.44±0.1 | -0.4±0.2 -0.42±0.1 -0.43±0.1 -0.43±0.2 | 0.919 0.991 0.991 0.991 | 0.45±0.1 0.34±0.1 0.35±0.1 0.38±0.1 | 0.34 ± 0.1 0.29 ± 0.1 0.34 ± 0.1 0.35 ± 0.1 0.33 ± 0.1 0.33 ± 0.1 | 0.048* 0.997 0.984 | 0.36±0.1 0.35±0.1 0.28±0.1 0.31±0.1 0.34±0.1 0.34±0.1 0.32±0 | 0.27±0.1 0.28±0.1 0.27±0.1 | 0.489 0.489 0.957 0.629 0.452 0.452 0.397 |
| Radial E _{rr} | Base Mid Apex Global | 18.6±9.7 | | 0.999 0.999 | 0.78±0.7 0.47±0.5 | 1.39±1.2 | 0.491 0.66 | -1.51±0.7 -0.94±0.6 | -1.78±1.4 -1.91±1.2 -0.95±0.7 -1.62±1.1 | 0.873 0.971 | -0.41±0.7 -0.19±0.5 | -0.4±0.6 | 0.958 0.958 |
| Surface Area E _a | Base Mid Apex Global | -23.9±2.7 -28.2±5.2 | -17.3±5.8 -18.8±7.2 -23.8±9.8 -19.5±7.3 | 0.25 0.323 | -1.34±0.1 -1.62±0.3 | -1.09±0.5 -1.42±0.5 | 0.605 0.753 | 1.29±0.2 1.64±0.5 | 0.88±0.2 0.98±0.2 1.28±0.5 1.02±0.3 | 0.088 0.272 | 0.98±0.2 1.25±0.3 | | 0.018* 0.082 |

543 Group 3: abnormal, slow progression (C; initial LVEF<55%, +2 years △LVEF%≤5); Group 4:

544 abnormal, fast progression (D; initial LVEF<55%, +2 years △LVEF%>5); *p<0.05, adjusted for

545 multiple comparisons.

546

547

549 **References**:

550

551 1. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J and Lochmüller H. Life 552 expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. 553 European Journal of Epidemiology. 2020;35:643-653. 554 Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S and Trifirò G. Global 2. 555 epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-556 analysis. Orphanet Journal of Rare Diseases. 2020;15. 557 Ryder S, Leadley RM, Armstrong N, Westwood M, De Kock S, Butt T, Jain M and 3. 558 Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an 559 evidence review. Orphanet Journal of Rare Diseases. 2017;12. 560 Meyers TA and Townsend D. Cardiac Pathophysiology and the Future of Cardiac 4. 561 Therapies in Duchenne Muscular Dystrophy. International Journal of Molecular Sciences. 562 2019;20:4098. 563 Shih JA, Folch A and Wong BL. Duchenne Muscular Dystrophy: the Heart of the Matter. 5. 564 Current Heart Failure Reports. 2020;17:57-66. 565 Angulski ABB, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J and Metzger JM. 6. 566 Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Frontiers in 567 Physiology. 2023;14. 568 Lee S, Lee M and Hor KN. The role of imaging in characterizing the cardiac natural 7. 569 history of Duchenne muscular dystrophy. Pediatric Pulmonology. 2021;56:766-781. 570 Earl CC, Soslow JH, Markham LW and Goergen CJ. Myocardial strain imaging in 8. 571 Duchenne muscular dystrophy. Frontiers in Cardiovascular Medicine. 2022;9. 572 Blaszczyk E, Gröschel J and Schulz-Menger J. Role of CMR Imaging in Diagnostics and 9. 573 Evaluation of Cardiac Involvement in Muscle Dystrophies. Current Heart Failure Reports. 574 2021;18:211-224. 575 10. Prakash N, Suthar R, Sihag BK, Debi U, Kumar RM and Sankhyan N. Cardiac MRI and 576 echocardiography for early diagnosis of cardiomyopathy among boys with Duchenne muscular 577 dystrophy: a cross-sectional study. Frontiers in Pediatrics. 2022;10:818608. 578 11. Lechner A, Herzig JJ, Kientsch JG, Kohler M, Bloch KE, Ulrich S and Schwarz EI. 579 Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational 580 study. ERJ Open Research. 2023;9:00176-2023. 581 Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, Pack N, Dibella E 12. 582 and Gottliebson WM. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne 583 muscular dystrophy? The International Journal of Cardiovascular Imaging. 2009;25:57-63. 584 Earl CC, Pyle VI, Clark SQ, Annamalai K, Torres PA, Quintero A, Damen FW, Hor KN, 13. 585 Markham LW, Soslow JH and Goergen CJ. Localized strain characterization of cardiomyopathy 586 in Duchenne muscular dystrophy using novel 4D kinematic analysis of cine cardiovascular 587 magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2023;25. 588 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, 14. 589 Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez 590 AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, 591 Stevenson LW, Vardeny O, Vest AR and Yancy CW. 2022 AHA/ACC/HFSA Guideline for the 592 Management of Heart Failure: A Report of the American College of Cardiology/American Heart 593 Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145.

Raucci FJ, Xu M, George-Durrett K, Crum K, Slaughter JC, Parra DA, Markham LW 594 15. 595 and Soslow JH. Non-contrast cardiovascular magnetic resonance detection of myocardial fibrosis 596 in Duchenne muscular dystrophy. Journal of Cardiovascular Magnetic Resonance. 2021;23. 597 16. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, 598 Rumberger JA, Ryan T and Verani MS. Standardized Myocardial Segmentation and 599 Nomenclature for Tomographic Imaging of the Heart. Circulation. 2002;105:539-542. 600 17. Dann MM, Clark SQ, Trzaskalski NA, Earl CC, Schepers LE, Pulente SM, Lennord EN, 601 Annamalai K, Gruber JM and Cox A. Quantification of Murine Myocardial Infarct Size using 2D 602 and 4D High Frequency Ultrasound. American Journal of Physiology-Heart and Circulatory 603 Physiology. 2022. 604 18. Damen FW, Salvas JP, Pereyra AS, Ellis JM and Goergen CJ. Improving characterization 605 of hypertrophy-induced murine cardiac dysfunction using four-dimensional ultrasound derived 606 strain mapping. American Journal of Physiology-Heart and Circulatory Physiology. 2021. 607 Leyba K, Paiyabhroma N, Salvas JP, Damen FW, Janvier A, Zub E, Bernis C, Rouland 19. 608 R, Dubois CJ, Badaut J, Richard S, Marchi N, Goergen CJ and Sicard P. Neurovascular hypoxia 609 after mild traumatic brain injury in juvenile mice correlates with heart-brain dysfunctions in 610 adulthood. Acta Physiologica. 2023;238. 611 Hor KN, Kissoon N, Mazur W, Gupta R, Ittenbach RF, Al-Khalidi HR, Cripe LH, Raman 20. 612 SV, Puchalski MD, Gottliebson WM and Benson DW. Regional Circumferential Strain is a 613 Biomarker for Disease Severity in Duchenne Muscular Dystrophy Heart Disease: A Cross-614 Sectional Study. Pediatric Cardiology. 2015;36:111-119. 615 21. Kerstens TP, van Everdingen WM, Habets J, van Dijk AP, Helbing WA, Thijssen DH and Ten Cate FEU. Left ventricular deformation and myocardial fibrosis in pediatric patients 616 617 with Duchenne muscular dystrophy. International Journal of Cardiology. 2023;388:131162. Skaarup KG, Lassen MCH, Marott JL, Biering-Sørensen SR, Jørgensen PG, Appleyard 618 22. 619 M, Berning J, Høst N, Jensen G, Schnohr P, Søgaard P, Gislason G, Møgelvang R and Biering-620 Sørensen T. The impact of cardiovascular risk factors on global longitudinal strain over a decade 621 in the general population: the copenhagen city heart study. The International Journal of 622 Cardiovascular Imaging. 2020;36:1907-1916. 623 Grossman W, Jones D and McLaurin LP. Wall stress and patterns of hypertrophy in the 23. 624 human left ventricle. Journal of Clinical Investigation. 1975;56:56-64. 625 24. Siddiqui S, Alsaied T, Henson SE, Gandhi J, Patel P, Khoury P, Villa C, Ryan TD, 626 Wittekind SG, Lang SM and Taylor MD. Left Ventricular Magnetic Resonance Imaging Strain 627 Predicts the Onset of Duchenne Muscular Dystrophy-Associated Cardiomyopathy. *Circulation:* 628 Cardiovascular Imaging. 2020;13. 629 Markham LW, Michelfelder EC, Border WL, Khoury PR, Spicer RL, Wong BL, Benson 25. 630 DW and Cripe LH. Abnormalities of Diastolic Function Precede Dilated Cardiomyopathy 631 Associated with Duchenne Muscular Dystrophy. Journal of the American Society of 632 Echocardiography. 2006;19:865-871.

Figure 1:


Α

В

| DMD-Associated | Cardiomyopathy Staging |
|----------------------------|---|
| Stage A: At risk for HF | LVEF≥55%, LGE (-) |
| Stage B: Pre-HF | LVEF>55%, LGE(+) |
| Stage C: Symptomatic HF | 40% <lvef<55%, -)<="" lge(+="" th=""></lvef<55%,> |
| Stage D: Advanced HF | LVEF<40%, LGE(+) |

C

Deceased






Table 1:

| | Visit 1 | Visit 2 | Visit 3 | | |
|-----------------------------|------------------|------------------|------------------|--|--|
| | (n=40) | (n=38) | (n=36) | | |
| Age (years) | 12.4 [10.5-16.6] | 12.8 [11.5-17.0] | 13.7 [12.5-17.0] | | |
| Height (cm) | 146 [127-163] | 152 [142-161] | 152 [142-163] | | |
| Weight (kg) | 47.2 [36.4-65.0] | 53.6 [39.5-69.9] | 58.5 [43.2-72.8] | | |
| BSA (m^2) | 1.4 [1.2-1.7] | 1.5 [1.3-1.8] | 1.6 [1.3-1.8] | | |
| HR (BPM) | 103 [92-116] | 97 [89-105] | 100 [89-111] | | |
| Systolic (mmHg) | 115 [107-120] | 117 [106-123] | 115 [105-120] | | |
| Diastolic (mmHg) | 66 [61-74] | 68 [63-74] | 69 [59-76] | | |
| LVEF (%) | 59 [51-62] | 57 [49-59] | 55 [49-58] | | |
| LVEDVI (ml/m ²) | 59 [54-70] | 61 [52-68] | 65 [57-71] | | |
| LVESVI (ml/m ²) | 24 [20-34] | 26 [22-33] | 29 [25-34] | | |
| CO (L/min) | 4.9 [4.0-5.8] | 4.7 [4.1-5.3] | 5.1 [4.0-6.0] | | |
| LVEF<55%, n(%) | 12 (30) | 16 (42) | 18 (50) | | |
| +LGE, n(%) | 26 (65) | 29 (76) | 34 (94) | | |
| Stage A, n(%) | 14 (35) | 9 (24) | 2 (6) | | |
| Stage B, n(%) | 14 (35) | 13 (34) | 16 (44) | | |
| Stage C, n(%) | 9 (22.5) | 14 (37) | 16 (44) | | |
| Stage D, n(%) | 3 (7.5) | 2 (5) | 2 (6) | | |

BSA, body surface area; HR, heart rate; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end diastolic volume indexed to BSA; LVESVI, left ventricular end systolic volume indexed to BSA; LVCO, left ventricular cardiac output; LGE, late gadolinium enhancement.
Stage A, LVEF>55%, LGE(-); Stage B, LVEF>55%, LGE(+); Stage C, 40%<LVEF<55%, LGE(+); Stage D, LVEF<40%, LGE(+). Values reported as median [interquartile range] or as number of subjects (percentage of group)—n(%).




Figure 3:





Figure 4:

Initial Visit Group-Averaged Strain

Global Peak Strain








Figure 6:





Initial Visit Peak Strain



Global

п

Ŧ

Global

